Volume 7.28 | Jul 23

Cord Blood News 7.28 July 23, 2015
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CBN on Twitter
PRC2 Inhibition Counteracts the Culture-Associated Loss of Engraftment Potential of Human Cord Blood-Derived Hematopoietic Stem and Progenitor Cells
Scientists profiled global and local epigenotypes during the expansion of human cord blood hematopoietic stem and progenitor cells. They revealed chromatin dynamics that underlie the culture-associated loss of engraftment potential. [Sci Rep] Full Article
Learn more about our standardized tools for cord blood banking
PUBLICATIONS (Ranked by impact factor of the journal)
Scalable Efficient Expansion of Mesenchymal Stem Cells in Xeno Free Media Using Commercially Available Reagents
XcytePLUS™ media, a human platelet lysate based product, was used to supplement culture medium at 5, 7.5 and 10% and compared to fetal calf serum (FCS) at 10%, for human umbilical cord mesenchymal stem cell expansion. They demonstrated equivalent or superior effects of human platelet lysate compared to standard FCS supplemented media, based on doubling rate, without loss of identity or function, as demonstrated with flow cytometry characterization. [J Transl Med] Full Article

Different Procoagulant Activity of Therapeutic Mesenchymal Stromal Cells Derived from Bone Marrow and Placental Decidua
Researchers present a first safety follow-up on their clinical experience with placenta-derived decidual stromal cells, used as supportive immunomodulatory and regenerative therapy for patients with severe complications after allogeneic hematopoietic stem cell transplantation. [Stem Cells Dev] Abstract

Metabolic Syndrome in Adults Who Received Hematopoietic Stem Cell Transplantation for Acute Childhood Leukemia: An LEA Study
Researchers evaluated prospectively the incidence and risk factors of the metabolic syndrome and its components in 170 adult patients who received an hematopoietic stem cell transplantation for childhood. [Bone Marrow Transplant] Abstract

Wharton’s Jelly-Derived Mesenchymal Stem Cells Alleviate Memory Deficits and Reduce Amyloid-β Deposition in an APP/PS1 Transgenic Mouse Model
Investigators evaluated the therapeutic effect of Wharton’s Jelly-derived mesenchymal stem cells transplantation on the neuropathology and memory deficits in amyloid precursor protein and presenilin-1 double-transgenic mice. [Clin Exp Med] Abstract

Dehydrated Human Amnion/Chorion Membrane Regulates Stem Cell Activity In Vitro
PURION® Processed dehydrated human amnion/chorion membrane allografts were evaluated for their ability to alter stem cell activity in vitro. [J Biomed Mater Res B Appl Biomater] Abstract | Press Release

Comparative Analysis of Human Mesenchymal Stem Cells from Fetal-Bone Marrow, Adipose Tissue, and Warton’s Jelly as Sources of Cell Immunomodulatory Therapy
Scientists compared human fetal bone marrow, adipose tissue, and Warton’s jelly-derived MSCs (WJ-MSCs) for surface antigen expression, differentiation ability, proliferation capacity, clonality, tolerance for aging, gene expression, and whether IFN-γ affected WJ-MSC gene expression, as determined by real time quantitative PCR. [Hum Vaccin Immunother] Abstract

Effect of Targeted Ovarian Cancer Therapy Using Amniotic Fluid Mesenchymal Stem Cells Transfected with Enhanced Green Fluorescent Protein-Human Interleukin-2 in Vivo
Investigators found that amniotic fluid mesenchymal stem cells (AF-MSCs) exhibited high motility during migration in vivo and the vector, pEGFP‑hIL‑2, can be stably transfected into AF‑MSCs. Following stable transfection, this type of stem cell was able to successfully transport the therapeutic gene, IL-2, migrate to the ovarian cancer tumor site to secrete the functional IL-2 and treat the tumor. [Mol Med Rep] Abstract

Only One of These Antibodies Will Work for Your Cell Analysis. We Provide Streamlined Solutions that are Reliable and Save You Time
Lost in Translation: Pluripotent Stem Cell-Derived Hematopoiesis
While the generation of fully defined hematopoietic stem cells from pluripotent stem cells (PSCs) remains challenging in vitro, the authors underline the instructive role of cell extrinsic factors such as cytokines for the generation of PSC-derived mature hematopoietic cells. [EMBO Mol Med] Full Article

Cryopreservation of Mesenchymal Stromal Cells Derived from Various Tissues
The authors present an overview of the identification of mesenchymal stromal cells (MSCs), their tissue sources and the properties that render them suitable as a cellular therapeutic. They discuss the responses of cells during freezing and focus on the traditional and novel approaches used to cryopreserve MSCs. [Cryobiology] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Stem Cells & Regenerative Medicine Congress 2015
CBR & NAHN Partner To Heighten Awareness of the Importance Of Preserving Umbilical Cord Blood Stem Cells
Cord Blood Registry® (CBR®) and the National Association of Hispanic Nurses® (NAHN®) announced that they have entered into a collaboration focused on educating health care providers and the public about the importance of preserving umbilical cord blood stem cells. [Cord Blood Registry®] Press Release

Amgen Announces Positive BLINCYTO® (Blinatumomab) Phase II Study Results in Patients with Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen announced the top-line results of a Phase II open-label, single-arm, multicenter trial to evaluate the efficacy and safety of BLINCYTO® in adults with relapsed or refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. [Amgen] Press Release

Medtown Ventures, LLC Announces Exclusive License Agreement with Georgia Tech Research Corporation
Medtown Ventures, LLC announced that it has entered into an exclusive license agreement with Georgia Tech Research Corporation for a new adhesive-signature based stem cell selection and isolation technology. [Medtown Ventures, LLC] Press Release

From our sponsor: 3D intestinal organoid culture is made easy with IntestiCult™. Request a sample.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cell Culture 2016
February 2-4, 2016
London, United Kingdom

Visit our events page to see a complete list of events in the cord blood community.
NEW Postdoctoral Fellow – Hematopoietic Regeneration and Myeloid Malignancies (Weill-Cornell Medical College)

NEW Research Associate – Cell Biology (Editas Medicine)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Independent Junior Group Leader – Lymphopoiesis or Gene Regulation/Nuclear Architecture in the Hematopoietic System (Max-Planck-Institute)

Data Coordinator – Hematological Malignancies (Fred Hutchinson Cancer Research Center)

Clinical Research Coordinator – Chronic Lymphocytic Leukemia (Fred Hutchinson Cancer Research Center)

Regulatory Coordinator – Leukemia Research (Weill Cornell College of Medicine)

PhD Position – Drug Releasing, Nanostructured Biomaterials for Adult Stem Cells (Karlsruhe Institute of Technology)

Postdoctoral Fellow – Immune Reconstitution in Hematopoietic Stem Cell Transplantation (Stanford University)

Research Associate – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us